KR20210119428A - 미세혈전증의 치료 및 예방을 위한 플라스미노겐 - Google Patents

미세혈전증의 치료 및 예방을 위한 플라스미노겐 Download PDF

Info

Publication number
KR20210119428A
KR20210119428A KR1020217025524A KR20217025524A KR20210119428A KR 20210119428 A KR20210119428 A KR 20210119428A KR 1020217025524 A KR1020217025524 A KR 1020217025524A KR 20217025524 A KR20217025524 A KR 20217025524A KR 20210119428 A KR20210119428 A KR 20210119428A
Authority
KR
South Korea
Prior art keywords
plasminogen
patient
plg
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217025524A
Other languages
English (en)
Korean (ko)
Inventor
슈테판 티. 키시그
리카르다 벨츠
한네 리케 게르딩
마르크 마쥬르
한스-요아힘 안데르스
충슈 시
크리스토프 쉼멜페닉
사티쉬 쿠마르 데바라푸
Original Assignee
프리비파하르마, 컨설팅 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리비파하르마, 컨설팅 게엠베하 filed Critical 프리비파하르마, 컨설팅 게엠베하
Publication of KR20210119428A publication Critical patent/KR20210119428A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217025524A 2019-01-24 2020-01-24 미세혈전증의 치료 및 예방을 위한 플라스미노겐 Ceased KR20210119428A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153572.3 2019-01-24
EP19153572 2019-01-24
PCT/EP2020/051733 WO2020152322A1 (en) 2019-01-24 2020-01-24 Plasminogen for treating and preventing microthrombosis

Publications (1)

Publication Number Publication Date
KR20210119428A true KR20210119428A (ko) 2021-10-05

Family

ID=65234430

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217025524A Ceased KR20210119428A (ko) 2019-01-24 2020-01-24 미세혈전증의 치료 및 예방을 위한 플라스미노겐

Country Status (9)

Country Link
US (1) US20220072110A1 (https=)
EP (1) EP3914288A1 (https=)
JP (1) JP2022518496A (https=)
KR (1) KR20210119428A (https=)
CN (1) CN113597313A (https=)
AU (1) AU2020212404B2 (https=)
BR (1) BR112021014068A2 (https=)
CA (1) CA3127375A1 (https=)
WO (1) WO2020152322A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258590A1 (en) 2021-06-08 2022-12-15 Previpharma Consulting Gmbh Process for isolating plasminogen from a blood plasma fraction
WO2025132796A1 (en) 2023-12-21 2025-06-26 Previpharma Consulting Gmbh Process for isolating glu-plasminogen from a solution

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (https=) * 1973-12-18 1977-04-22 Choay Sa
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
ES2982294T3 (es) * 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
ES2968254T3 (es) * 2015-12-18 2024-05-08 Talengen Int Ltd Plasminógeno para su uso en la prevención o el tratamiento de la trombosis aguda y la trombosis crónica
DK3391902T5 (da) * 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
KR102640024B1 (ko) * 2017-03-09 2024-02-22 프리비파하르마, 컨설팅 게엠베하 혈액 분획으로부터의 Glu-플라스미노겐의 제조 및 용도

Also Published As

Publication number Publication date
AU2020212404B2 (en) 2025-11-27
WO2020152322A1 (en) 2020-07-30
JP2022518496A (ja) 2022-03-15
EP3914288A1 (en) 2021-12-01
US20220072110A1 (en) 2022-03-10
CN113597313A (zh) 2021-11-02
AU2020212404A1 (en) 2021-08-26
BR112021014068A2 (pt) 2021-09-21
CA3127375A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
Majeed et al. Bleeding and antidotes in new oral anticoagulants
Morris et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis
Sharma et al. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension
Larsson et al. Valproic acid selectively increases vascular endothelial tissue‐type plasminogen activator production and reduces thrombus formation in the mouse
McKenna Abnormal coagulation in the postoperative period contributing to excessive bleeding
CA2684075A1 (en) Providing hemostasis in anticoagulated blood by using zeolites
JP7269184B2 (ja) 血液画分からのＧｌｕ－プラスミノーゲンの製造および使用
Swieringa et al. Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding
Lassila et al. Mast cell–derived heparin proteoglycans as a model for a local antithrombotic
Resiere et al. Preclinical evaluation of the neutralizing ability of a monospecific antivenom for the treatment of envenomings by Bothrops lanceolatus in Martinique
JP6894993B2 (ja) 血漿タンパク質にコンジュゲートしたヘパリンを含む治療用ａｐａｃ分子
Jaques et al. Pharmacodynamics and clinical effectiveness of heparin
Sakamaki et al. Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension
KR20210119428A (ko) 미세혈전증의 치료 및 예방을 위한 플라스미노겐
Cattaneo The use of desmopressin in open‐heart surgery
Arnoux et al. Intraoperative evolution of coagulation parameters and t-PA/PAI balance in orthotopic liver transplantation
LeVeen et al. Coagulopathy post peritoneovenous shunt
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Novacek et al. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin
EA035358B1 (ru) Способ, набор и комбинация для лечения субъекта с симптомами инсульта или острого инфаркта миокарда
Fattorutto et al. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits
Bhagirath et al. Management of bleeding complications in the anticoagulated patient
Cole et al. Ancrod versus heparin for anticoagulation during vascular surgical procedures
Di Perri et al. Defibrotide therapy for thrombophlebitis–controlled clinical trial
Giles et al. The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000